School of Medicine


Showing 31-40 of 43 Results

  • Teri A Longacre

    Teri A Longacre

    Richard L. Kempson, MD, Professor in Surgical Pathology
    On Leave from 09/01/2023 To 05/16/2024

    Current Research and Scholarly InterestsGynecological, breast and gastrointestinal pathology with major emphasis on ovarian cancer and ovarian tumors of low malignant potential. Pathology of familial and hereditary breast-ovarian-GI cancer.

  • Dr. Michael T. Longaker

    Dr. Michael T. Longaker

    Deane P. and Louise Mitchell Professor in the School of Medicine and Professor, by courtesy, of Materials Science and Engineering

    Current Research and Scholarly InterestsWe have six main areas of current interest: 1) Cranial Suture Developmental Biology, 2) Distraction Osteogenesis, 3) Fibroblast heterogeneity and fibrosis repair, 4) Scarless Fetal Wound Healing, 5) Skeletal Stem Cells, 6) Novel Gene and Stem Cell Therapeutic Approaches.

  • Billy W Loo, Jr, MD PhD FASTRO FACR

    Billy W Loo, Jr, MD PhD FASTRO FACR

    Professor of Radiation Oncology (Radiation Therapy)

    Current Research and Scholarly InterestsMy clinical specialty is radiation treatment of thoracic cancers.

    My research is on developing next-generation ultra-rapid radiation therapy technology (PHASER) and studying the radiobiological effects of FLASH treatment.

    My clinical research is on advanced 4-D image-guided radiation therapy and stereotactic ablative radiotherapy (SABR), and functional and metabolic imaging and imaging biomarkers.

  • Karl Lorenz

    Karl Lorenz

    Professor of Medicine (Primary Care and Population Health)

    BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.

  • Kate Lorig

    Kate Lorig

    Professor (Research) of Medicine (Immunology and Rheumatology), Emerita

    Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.

  • Anson Lowe

    Anson Lowe

    Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus

    Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.

  • Robert Lowsky

    Robert Lowsky

    Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.

  • Bingwei Lu

    Bingwei Lu

    Professor of Pathology

    Current Research and Scholarly InterestsWe are interested in understanding how neural stem cells balance their self-renewal and differentiation and how deregulation of this process can result in brain tumor. We are also interested in mechanisms of neurodegeneration in Alzheimer’s and Parkinson’s diseases. We are using both Drosophila and mammalian models to address these fundamental questions.

  • Sydney X. Lu

    Sydney X. Lu

    Assistant Professor of Medicine (Hematology)

    BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
    Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
    The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.

    Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
    1) normal and pathologic immunity and immunotherapy
    2) cancer biology
    3) normal and malignant hematopoiesis

  • Ying Lu

    Ying Lu

    Professor of Biomedical Data Science and, by courtesy, of Epidemiology

    Current Research and Scholarly InterestsBiostatistics, clinical trials, statistical evaluation of medical diagnostic tests, radiology, osteoporosis, meta-analysis, medical decision making